Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Inhalers used to treat symptoms of respiratory disease can be potent sources of greenhouse gases. Drugmakers are planning to ...

GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

The way forward, then, is to deliver truly personalised medicines and care. For industry, this means developing therapies ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...